Entropy Technologies LP Has $881,000 Stock Position in Baxter International Inc. (NYSE:BAX)

Entropy Technologies LP boosted its position in Baxter International Inc. (NYSE:BAX - Free Report) by 213.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,192 shares of the medical instruments supplier's stock after purchasing an additional 15,794 shares during the quarter. Entropy Technologies LP's holdings in Baxter International were worth $881,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First PREMIER Bank bought a new stake in shares of Baxter International in the third quarter valued at about $25,000. Innealta Capital LLC acquired a new position in shares of Baxter International during the 2nd quarter worth approximately $27,000. Fortitude Family Office LLC bought a new position in shares of Baxter International during the third quarter worth approximately $38,000. LRI Investments LLC acquired a new stake in shares of Baxter International in the first quarter valued at approximately $39,000. Finally, Versant Capital Management Inc boosted its stake in shares of Baxter International by 974.2% in the second quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 1,208 shares during the period. 90.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BAX shares. The Goldman Sachs Group raised their price target on Baxter International from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered their target price on Baxter International from $44.00 to $42.00 and set a "neutral" rating for the company in a research note on Wednesday, August 7th. Stifel Nicolaus dropped their price objective on shares of Baxter International from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Monday. Wells Fargo & Company reduced their price objective on Baxter International from $44.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 7th. Finally, StockNews.com cut Baxter International from a "buy" rating to a "hold" rating in a report on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $40.91.

Baxter International Trading Down 2.8 %

BAX stock traded down $0.92 during midday trading on Thursday, hitting $31.71. The stock had a trading volume of 2,215,429 shares, compared to its average volume of 4,061,080. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35. The firm has a market cap of $16.18 billion, a P/E ratio of 161.66, a price-to-earnings-growth ratio of 11.44 and a beta of 0.60. The business has a fifty day moving average price of $37.13 and a two-hundred day moving average price of $35.94. Baxter International Inc. has a 1-year low of $31.61 and a 1-year high of $44.01.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.78 by $0.02. Baxter International had a return on equity of 18.19% and a net margin of 0.77%. The company had revenue of $3.85 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same period in the previous year, the business earned $0.68 EPS. The firm's revenue was up 3.8% compared to the same quarter last year. On average, sell-side analysts predict that Baxter International Inc. will post 2.33 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Friday, November 29th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 2.14%. The ex-dividend date of this dividend is Friday, November 29th. Baxter International's dividend payout ratio (DPR) is 580.03%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.